Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration

Expert Opinion on Biological Therapy

Volumn 15, Issue 9, 2015, Pages 1349-1358

  Yazdi, Mohammad Hossein ^a   Faramarzi, Mohammad Ali ^b   Nikfar, Shekoufeh ^c   Falavarjani, Khalil Ghasemi ^d   Abdollahi, Mohammad ^b,e  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aflibercept; anti VEGF; ranibizumab; wet age related macular degeneration

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; DRUG EFFICACY; DRUG INDICATION; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; WET MACULAR DEGENERATION; EYE; IMMUNOLOGY; MACULAR DEGENERATION; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EYE; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938843088     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1057565     Document Type: Review

References (58)

1. Nivison-Smith L, Milston R, Madigan M, Kalloniatis M. Age-related macular degeneration: linking clinical presentation to pathology. Optom Vis Sci 2014; 91 (8): 832-48
2. Singer M. Advances in the management of macular degeneration. F1000Prime Rep 2014; 6: 29
3. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008; 68 (8): 1029-36
4. FDA approves lucentis for wet age-related macular degeneration. Available from: http://www.drugs.com/news/fda-approves-lucentis-wet-age-related-macular-degeneration-1846.html. [Last accessed 30 January 2015]
5. Eylea Approval History. Available from: http://www.drugs.com/history/eylea.html. [Last accessed 30 January 2015]
6. Chew EY, Clemons TE, SanGiovanni JP, et al. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-15
7. Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 2007; 91: 1173-6
8. FDA approves new biologic treatment for wet age-related macular degeneration. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108685.htm. [Last accessed 30 January 2015]
9. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-48
11. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44
12. Gharbiya M, Parisi F, Cruciani F, et al. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen. Retina 2014; 34 (2): 298-305
13. Maier M, Perz C, Bockmaier J, et al. Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections. Ophthalmologe 2013; 110 (12): 1171-8
14. Kramann CA, Schöpfer K, Lorenz K, et al. Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmol 2012; 90 (5): 487-91
15. Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. Br J Ophthalmol 2014; 98 (7): 956-60
16. Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014; 121: 2181-92
17. Brown DM, Chen E, Mariani A, Major JC Jr,; SAVE Study Group. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary endpoint. Ophthalmology 2013; 120 (2): 349-54
18. Kodjikian L, Souied EH, Mimoun G, et al. GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013; 120 (11): 2300-9
19. Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013; 27: 787-94
20. FDA Drug Approvals Database. Food and Drug Administration. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm314438.htm. August 3, 2012. Retrieved 2013-10-16. [Last accessed 08 February 2015]
21. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98 (12): 1636-41
22. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121 (1): 193-201
23. Singh RP, Srivastava S, Ehlers JP, et al. A single-arm,investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol 2014; 98 (Suppl 1): i22-7
24. Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013; 7: 711-22
25. Nguyen QD, Campochiaro PA, Shah SM, et al. Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2012; 28 (6): 581-8
26. Safety and efficacy of repeated intravitreal administration of vascular endothelial growth factor (VEGF) trap in patients with wet age-related macular degeneration (AMD). Available from: https://clinicaltrials.gov/ct2/show/results/NCT00320788?term=Aflibercept+and+AMD&recr=Completed&rslt=With&type=Intr&rank=1§=X301256#evnt. [Last accessed 14 February 2015]
27. Randomized, single-masked, long-term, safety and tolerability study of VEGF trap-eye in AMD. Available from: https://clinicaltrials.gov/ct2/show/NCT00527423?term=Aflibercept+and+AMD&recr=Completed&rslt=With&type=Intr&rank=2§=X980156#outcome3. [Last accessed 14 February 2015]
28. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156 (1): 15-22
29. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97 (8): 1032-5
30. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119 (12): 2537-48
31. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33 (8): 1605-12
32. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-44
33. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118 (9): 1819-26
34. Mavija M, Alimanovic E, Jaksic V, et al. Therapeutic modalities of exudative age related macular degeneration. Med Arh 2014; 68 (3): 204-8
35. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONTBLANC study results. Ophthalmology 2012; 119 (5): 992-1000
36. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5 (2): 123-32
37. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16
38. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119 (7): 1388-98
39. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119 (7): 1399-411
40. El-Mollayess GM, Noureddine BN, Bashshur ZF. Bevacizumab andneovascular age relatedmacular degeneration: pathogenesis and treatment. Semin Ophthalmol 2011; 26: 69-76
41. Hashemi S, Faramarzi MA, Ghasemi Falavarjani K, Abdollahi M. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opin Biol Ther 2014; 14 (12): 1837-48
42. Cho H, Weber ML, Shah CP, Heier JS. Initial utilization of aflibercept in exudative age-related macular degeneration. Eur J Ophthalmol 2014; 24 (4): 576-81
43. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
44. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 2012; 96: 1157-8
45. Sene A, Chin-Yee D, Apte RS. Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med 2015; 21 (1): 43-51
46. Klettner A, Kauppinen A, Blasiak J, et al. Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization. Int J Biochem Cell Biol 2013; 45 (7): 1457-67
47. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 8: CD005139
48. Dashti-Khavidaki S, Abdollahi M. Intravitreal administration of bevacizumab: pros and cons. Daru 2015; 23: 27
49. Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye(Lond) 2012; 26 (9): 1181-7
50. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31
51. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81 (2): 154-62
52. Tozer K, Roller AB, Chong LP, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 2013; 120: 2029-34
53. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005; 123: 1644-50
54. Sinha R, Choudhary S, Sinha S. Anti-vascular endothelial growth factor in ophthalmology. Indian J Ophthalmol 2009; 57: 330-5
55. Querques G, Capuano V, Frascio P, et al. Emerging therapeutic options in age-related macular degeneration. Ophthalmic Res 2015; 53: 194-9
56. Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 2014; 98 (7): 951-5
57. Sizmaz S, Kucukerdonmez C, Kal A, et al. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab. Eur J Ophthalmol 2014; 24 (6): 904-10
58. Kent JS, Iordanous Y, Mao A, et al. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Can J Ophthalmol 2012; 47 (2): 159-64